Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination
- PMID: 18852002
- DOI: 10.1016/j.vaccine.2008.09.064
Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination
Abstract
To study the pertussis-specific immune response of adolescents with different prevaccination schedules, we measured the humoral and cell-mediated immunity (CMI) to pertussis antigens before and after a five-component Tdap booster vaccination in 78 adolescents, who had previously received either five doses of a two-component acellular pertussis vaccine (aP; last dose age 4-6 years), four doses of aP (last dose age 18-24 months), or four doses of whole cell pertussis vaccine (wcP; last dose age 18-24 months). The proportion of participants with a twofold rise in titre was 79% against pertussis toxin (PT), 94% against filamentous hemagglutinin (FHA), and 99% against pertactin (PRN) without significant differences between the three groups. However, participants with primary wcP vaccination showed higher postvaccination titres to pertussis toxin (geometric mean titre, GMT 50.3EU/ml) than those with either four (GMT 17.1EU/ml) or five (GMT 16.4EU/ml) previous aP doses. CMI indices to PT, FHA, PRN and fimbriae (FIM) increased after vaccination and were similar between groups. The current adolescent Tdap booster immunization induced good humoral and cellular immune response to pertussis. The higher antibody titres to pertussis toxin may indicate a more effective priming of B cell memory after primary whole-cell vaccination.
Similar articles
-
Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.Clin Infect Dis. 2004 Jul 15;39(2):179-85. doi: 10.1086/421943. Epub 2004 Jul 2. Clin Infect Dis. 2004. PMID: 15307026
-
Immunity to pertussis 5 years after booster immunization during adolescence.Clin Infect Dis. 2007 May 15;44(10):1271-7. doi: 10.1086/514338. Epub 2007 Apr 2. Clin Infect Dis. 2007. PMID: 17443462
-
Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.Vaccine. 2013 Jan 2;31(2):387-93. doi: 10.1016/j.vaccine.2012.10.105. Epub 2012 Nov 8. Vaccine. 2013. PMID: 23142306 Clinical Trial.
-
Overview of recent clinical trials of acellular pertussis vaccines.Biologicals. 1999 Jun;27(2):79-86. doi: 10.1006/biol.1999.0184. Biologicals. 1999. PMID: 10600188 Review.
-
[Prevention of pertussis and high expectations concerning vaccines].Przegl Epidemiol. 2004;58 Suppl 1:39-43. Przegl Epidemiol. 2004. PMID: 15807156 Review. Polish.
Cited by
-
Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines.Hum Vaccin Immunother. 2024 Dec 31;20(1):2352909. doi: 10.1080/21645515.2024.2352909. Epub 2024 May 16. Hum Vaccin Immunother. 2024. PMID: 38752802 Free PMC article.
-
Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age.PLoS One. 2012;7(7):e41928. doi: 10.1371/journal.pone.0041928. Epub 2012 Jul 31. PLoS One. 2012. PMID: 22860033 Free PMC article.
-
Waning and aging of cellular immunity to Bordetella pertussis.Pathog Dis. 2015 Nov;73(8):ftv071. doi: 10.1093/femspd/ftv071. Epub 2015 Sep 13. Pathog Dis. 2015. PMID: 26371178 Free PMC article. Review.
-
Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?Clin Vaccine Immunol. 2012 Jun;19(6):875-80. doi: 10.1128/CVI.05686-11. Epub 2012 Apr 25. Clin Vaccine Immunol. 2012. PMID: 22539469 Free PMC article.
-
Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.Clin Vaccine Immunol. 2011 Jun;18(6):954-62. doi: 10.1128/CVI.00561-10. Epub 2011 Apr 20. Clin Vaccine Immunol. 2011. PMID: 21508166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources